Black Diamond Therapeutics Inc (BDTX)
2.865
-0.26
(-8.47%)
USD |
NASDAQ |
Nov 14, 16:00
2.85
-0.02
(-0.52%)
After-Hours: 20:00
Black Diamond Therapeutics Research and Development Expense (Quarterly): 12.91M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 12.91M |
| June 30, 2024 | 12.56M |
| March 31, 2024 | 13.54M |
| December 31, 2023 | 15.29M |
| September 30, 2023 | 16.15M |
| June 30, 2023 | 13.15M |
| March 31, 2023 | 14.75M |
| December 31, 2022 | 14.61M |
| September 30, 2022 | 15.85M |
| June 30, 2022 | 16.20M |
| March 31, 2022 | 17.79M |
| December 31, 2021 | 19.66M |
| Date | Value |
|---|---|
| September 30, 2021 | 27.63M |
| June 30, 2021 | 26.72M |
| March 31, 2021 | 22.82M |
| December 31, 2020 | 17.76M |
| September 30, 2020 | 12.93M |
| June 30, 2020 | 10.17M |
| March 31, 2020 | 7.354M |
| December 31, 2019 | 7.46M |
| September 30, 2019 | 5.634M |
| June 30, 2019 | 5.646M |
| March 31, 2019 | 3.013M |
| December 31, 2018 | 2.379M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.354M
Minimum
Mar 2020
27.63M
Maximum
Sep 2021
15.76M
Average
15.02M
Median
Research and Development Expense (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | 1.272B |
| Vanda Pharmaceuticals Inc | 16.66M |
| Ligand Pharmaceuticals Inc | 5.675M |
| Agios Pharmaceuticals Inc | 72.46M |
| ADMA Biologics Inc | 0.412M |